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Abstract
Background: Asthma is a chronic inflammatory disease of the airway that is characterized by a Th2-type of
immune response with increasing evidence for involvement of Th17 cells. The role of IL-6 in promoting effector T
cell subsets suggest that IL-6 may play a functional role in asthma. Classically IL-6 has been viewed as an
inflammatory marker, along with TNFa and IL-1b, rather than as regulatory cytokine.
Objective: To investigate the potential relationship between IL-6 and other proinflammatory cytokines, Th2/Th17
cytokines and lung function in allergic asthma, and thus evaluate the potential role of IL-6 in this disease.
Methods: Cytokine levels in induced sputum and lung function were measured in 16 healthy control and 18 mild-
moderate allergic asthmatic subjects.
Results: The levels of the proinflammatory biomarkers TNFa and IL-1b were not different between the control and
asthmatic group. In contrast, IL-6 levels were specifically elevated in asthmatic subjects compared with healthy
controls (p < 0.01). Hierarchical regression analysis in the total study cohort indicates that the relationship between
asthma and lung function could be mediated by IL-6. Among Th2 cytokines only IL-13 (p < 0.05) was also elevated
in the asthmatic group, and positively correlated with IL-6 levels (rS = 0.53, p < 0.05).
Conclusions: In mild-moderate asthma, IL-6 dissociates from other proinflammatory biomarkers, but correlates with
IL-13 levels. Furthermore, IL-6 may contribute to impaired lung function in allergic asthma.
Background
Asthma is a chronic inflammatory disease with patholo-
gical changes that occur in the lung such as airway eosi-
nophilia, mucus metaplasia and mucus hypersecretion.
These changes are associated with the development of a
CD4
+ Th2 type of immune response in the lung. This
immune response is characterized by the secretion of
IL-4, IL-5 and IL-13, with minimal production of the
Th1 type of cytokines (e.g. IFNg) [1]. More recent stu-
dies have also shown an association of CD4
+ Th17 type
of immune response with allergic airway inflammation,
but the contribution of Th17 cells and IL-17 to asthma
pathology is unclear [2-4]. Since the cytokine environ-
ment is one important factor that influences the fate of
effector CD4
+ T cells, it is possible that cytokines pro-
duced by structural elements in the lung influence the
local immune response. Although not part of the
immune system, lung epithelial cells can also contribute
to the type of immune response by secreting specific
cytokines. One of the cytokines that is produced by lung
epithelial cells is IL-6 [5,6] and increased production of
IL-6 by lung epithelial cells has been found in asthmatic
patients relative to control subjects [7,8].
IL-6 is a pleotropic cytokine that, together with TNFa
and IL-1b, has been traditionally considered as a bio-
marker of ongoing inflammation more than as a regula-
tory cytokine with potential to modulate the immune
response [9]. However, recent studies suggest that IL-6
plays an important role in determining the type of adap-
tive immune response, primarily in the differentiation of
effector CD4
+ T cells [10]. Specifically, IL-6 has been
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+ T cells
while suppressing Th1 differentiation through indepen-
dent pathways [10]. IL-6 can also modulate the intensity
of the immune response by inhibiting T regulatory
(Treg) cell development [11]. More recently, a number
of studies have shown that IL-6, together with TGF-b
promotes the generation of murine Th17 cells [12-14].
In humans however, the role of IL-6 in Th17 differentia-
tion is somewhat controversial since some studies sug-
gest that IL-6 is not required for Th17 development
[15,16] while other studies suggest that IL-6 synergizes
with IL-1b to promote Th17 differentiation [17]. Thus,
I L - 6m a yb eak e yf a c t o ri nd e t e r m i n i n gt h eb a l a n c eo f
CD4
+ T cells in becoming Treg or inflammatory Th17
cells.
Taken together, these findings suggest that rather than
being a marker of ongoing inflammation, IL-6 may have
a more functional role. To date, the animal studies
addressing the role of IL-6 in allergic airway inflamma-
tion have provided conflictive results. Studies using IL-6
deficient mice suggest IL-6 protects against airway
inflammation, while studies using neutralizing antibodies
suggest that IL-6 promotes allergic airway inflammation
[18,19]. Moreover, there has been relatively less interest
in the pathobiology of IL-6 in human asthma. In order
to investigate whether IL-6 might be more than an
inflammatory marker in asthma, we determined the
levels of IL-6, TNFa and IL-1b in induced sputum and
then related this to lung function in a group of mild-
moderate allergic asthmatic and healthy control subjects.
Methods
Subjects
We recruited mild-moderate allergic asthmatic and
healthy control adult subjects. Individuals were defined
as mild-moderate asthmatics according to the National
Institutes of Health Expert Panel Report 2 guidelines
[20]. The protocol was approved by the University of
Vermont Institutional Review Board and informed con-
sent was obtained. Asthmatic subjects (n = 18) had no
history of other cardiopulmonary diseases, were non-
smokers for at least 3 years and had less than a 5 pack
year history, FEV1 >70% predicted, exhibited positive
methacholine induced airway hyperresponsiveness
defined as a provocation concentration of methacholine
causing a 20% fall in FEV1 (PC20<8 mg/ml), and were
atopic by positive skin prick testing to one or more of
6 common Northeast regional allergen extracts. The
wheal flare response at sites of allergen exposure were
compared to negative control (glycerated saline) and
positive control (10 mg/ml histamine) skin prick sites in
order to determine atopic status. Healthy controls (n =
16) were negative for allergies and respiratory diseases,
exhibited normal pulmonary function tests and
PC20>16 mg/ml. A subgroup of asthmatic subjects were
taking inhaled corticosteroids daily in combination with
inhaled b-agonists (n = 9). Two out of the 9 asthmatic
patients using this treatment were also on antileuko-
trienes. The remaining subjects within the total asth-
matic group took inhaled b- a g o n i s t sa sn e e d e d( n=6 )
or were on no treatment at all (n = 3).
Study Design
Subjects underwent lung function testing and methacho-
line challenge as previously described [21,22]. At the
first visit, we obtained history and performed lung spiro-
metry and methacholine challenge. Skin prick testing to
Dermatophagoides pteronyssinus and D. farinae, cat dan-
der, grass and tree pollen, and Alternaria alternata was
conducted to establish atopic status at visit 2. Lung
spirometry and induced sputum collection was per-
formed at visit 3. Asthmatic subjects using albuterol and
salmeterol were instructed to discontinue drug use 8 h
and 24 h, respectively, prior to lung function testing.
Sputum Induction and Cytokine Analysis
Sputum samples were collected and processed as pre-
viously described [23]. Briefly, subjects were treated with
a bronchodilator and then administered increasing con-
centrations of nebulized hypertonic saline solution. At
select intervals during the procedure subjects were
encouraged to expectorate airway secretions through a
deep cough maneuver. Sputum plugs collected during
induction were treated with a volume of a 1:10 dilution
of dithiotreitol (DTT) (Sputolysin; Calbiochem) in PBS
that was four times their weight. Samples were centrifu-
gated at 400 g for 10 min. Supernatants were then col-
lected and stored at -80°C until cytokine analysis.
Cytospins were prepared from the remaining cell pellets
collected from the sputum preparation and analyzed by
the Giemsa staining method. Those samples that
demonstrated greater than 20% squamous cell contami-
nation were excluded. The majority of our sputum pre-
parations from healthy and asthmatic patients contained
<8% squamous cells. Analysis of lung epithelial cells
showed similar frequency of these cells in healthy (4.3%
+/- 5.2 SD) and asthmatic (4.8% +/- 5.7 SD) groups.
Sputum supernatants were analyzed for multiple
cytokines in triplicate using the Human 17-Plex Panel
(Bio-Rad). The Bio-plex system was chosen for cytokine
analysis since it has been validated by other studies for
cytokine detection in sputum supernatant [23,24]. Cyto-
kine standards were reconstituted in a PBS-DTT dilu-
tion buffer as a way to normalize the sputum samples
since a previous report has shown that DTT may inter-
fere with the detection of select cytokines by ELISA
[25], although we have not found that to be the case for
the cytokines that we measured. The cytokine mix
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construction of the standard curve. PBS-DTT dilution
buffer without cytokines was used as negative control.
The collected data was analyzed using the Bio-Plex
Manager Software (Bio-Rad). The limit of detection for
the Bio-plex assay ranged from 0.2-19.3 pg/ml according
to the manufacturer.
Statistical Analysis
Cell counts were expressed as median (interquartile
range, IQR). Due to the skewed nature of the distribu-
tions, non-parametric techniques were used to analyze
all data. Differences between asthmatic patients and
controls were examined using the Wilcoxon ranked-sum
test, while Spearman’s rank correlation coefficients (rS)
were computed for correlations. Particular interest
focused on whether cytokine levels could serve as
mediators in the relationship between disease status
(e.g. asthma) and lung function. Specifically, variables
are said to act as mediators when they represent a
mechanism through which the independent variable of
interest is able to influence the dependent variable of
interest [26]. This model assumes that there are two
effects of the independent variable: the direct effect and
an indirect effect acting through the mediator. In order
for a variable to function as a mediator, it must 1) be
significantly related to the independent variable, 2) be
significantly related to the dependent variable, and 3)
when both the independent variable and the potential
mediator are included in the same model, a previously
significant relationship between the independent and
dependent variables is reduced or eliminated. In order
to explore the potential mediation effects of the various
cytokines, we performed a hierarchical regression analy-
sis, beginning with a series of simple regression analyses
conducted to examine the relationship between disease
status and cytokine levels, cytokine levels and lung func-
tion and disease status and lung function. In the event
that the simple regression analyses suggest statistically
significant relationships, a multiple regression analysis is
performed with lung function as the dependant variable
and both disease status and cytokine levels as indepen-
dent variables. All continuous variables were trans-
formed to ranks prior to analysis [26]. A p < 0.05 was
considered significant.
Results
Subject demographics and lung function data for the
healthy control and mild-moderate asthmatic groups are
reported in Table 1. The mean age and male to female
ratio was similar in both groups. At baseline, the asth-
matic group exhibited a decrease in FEV1 in comparison
to control subjects. All of the asthmatic subjects were
atopic to at least one of the allergens tested in this
study, with Dermatophagoides being the most prevalent.
Fifty-percent of the group was sensitized to multiple
allergens.
Examination of cytokine levels in induced sputum
from the study groups showed that TNFa (Fig. 1A) and
IL-1b (Fig. 1B) levels were relatively low in the asth-
matics and were not statistically different from the levels
in the control group. No correlation between the levels
of these cytokines and medical treatment was found in
the asthmatic group (data not shown). Interestingly, in
contrast to TNFa and IL-1b, IL-6 levels were signifi-
cantly higher in the asthmatic group relative to control
subjects (Fig. 1C). Within the asthmatic population no
difference in IL-6 levels could be detected when asth-
matics were separated into groups based on medical
treatment (e.g. b-agonists alone or inhaled corticoster-
oids in combination with b-agonists) and those not on
medication (see Additional File 1). In addition to TNFa
and IL-1b, there was no significant difference in levels
of the proinflammatory cytokine monocyte chemoattrac-
tant protein-1 (MCP-1) [27] in the induced sputum
between asthmatics and controls (Fig. 1D).
Since IL-6 has been shown to be involved in the inflam-
matory response, we analyzed its association with TNFa
and IL-1b. Comparative analysis of IL-6, TNFa and
IL-1b showed a positive correlation between TNFa and
IL-1b in both control and asthmatic groups (Fig. 2A),
but there was no correlation between IL-6 and TNFa
(Fig. 2B) or IL-6 and IL-1b (Fig. 2C).
Table 1 Patient Demographics
Criteria Control Subjects Mild to Moderate
Asthmatic Subjects
Number 16 18
Sex (M/F) 6/10 7/11
Age, yr 25.2 ± 6.0 25.9 ± 9.4
Antileukotrienes 0 2
Inhaled Steriods 0 9
FEV1 % predicted 105.6 ± 11.4 90.2 ± 14.3
‡
FEV1/FVC % predicted 101.5 ± 4.1 87.6 ± 9.8
§
PC20 (mg/ml) >16 1.0 (0.48-2.1)
†
Squamous cells (%) 1.5 (3.8)* 2.0 (6.0)*
Lung Epithelial cells (%) 2.0 (5.3)* 2.5 (3.0)*
Eosinophils (%) 1.1 (3.0)* 2.0 (6.0)*
Neutrophils (%) 19.85 (21.1)* 6.95 (17.8)*
Values are reported as means ± SD unless otherwise indicated. Definition of
abbreviations: F = females, FEV1 = forced expiratory volume in 1 second,
FEV1/FVC = FEV1/forced vital capacity, M = males, PC20 = provocation
concentration of methacholine causing a 20% fall in FEV1. The percentage of
eosinophils and neutrophils are reported for induced sputum.
†Geometric mean (range)
*Median (interquartile range)
‡p = 0.004, asthmatic vs. control group
§p < 0.0001, asthmatic vs. control group
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with IL-6 levels in induced sputum. Pulmonary function
testing was performed on the same day that the induced
sputum was collected. Since most of the patients in this
study have mild asthma, with only a few of them exhi-
biting signs of moderate disease, the FEV1% predicted in
this group was clustered within a narrow range (Table
1). No statistically significant correlation could be found
between FEV1% predicted (data not shown), or FEV1/
forced vital capacity (FVC)% predicted with IL-6 levels
within the control or asthmatic groups (Fig. 3A).
Although it did not reach significance, there was a trend
towards an inverse correlation between the peak expira-
tory flow rate (PEFR) and IL-6 levels in the asthmatic
group relative to the control group (Fig. 3B).
Considering that the number of subjects per group
was limited, to further examine a potential link between
IL-6 and impaired lung function we used the hierarchi-
cal regression analysis in the total cohort (combining
control and asthmatic subjects). This type of analysis
builds from simple to multiple regression analyses to
investigate the potential contribution of mediators (e.g.
IL-6) to an already established relationship (e.g. asthma
and impaired lung function) (Fig. 3C). As expected from
the FEV1/FVC% predicted and PEFR values in asthmatic
and control subjects (Fig 3A and 3B), simple regression
analysis in the total cohort showed a significant inverse
correlation between disease status (asthma) and lung
function (Fig. 3C and Table 2, Path Z). Simple regres-
sion analysis also showed a direct correlation between
IL-6 levels and disease status (Table 2, Path X), as pre-
dicted from the results in Fig. 1C. Moreover, simple
regression analysis of IL-6 and lung function (Fig. 3C,
Path Y) showed a statistically significant inverse rela-
tionship between IL-6 and lung function, with increased
levels of IL-6 related to decreased FEV1/FVC% predicted
and PEFR values (Table 2, Path Y). We then performed
multiple regression analyses to explore whether IL-6
could be a mediator of the impaired lung function in
Figure 1 IL-6 but not TNFa or IL-1b is elevated in induced
sputum of mild-moderate asthmatic subjects. (A) TNFa,( B )I L - 1 b,
(C) IL-6 and (D) MCP-1 levels were analyzed in induced sputum of mild-
moderate asthmatic subjects (n = 18) and healthy controls (n = 16).
Figure 2 While TNFa correlates with IL-1b in induced sputum,
neither correlates with IL-6 in mild-moderate asthmatic
subjects. (A) Correlative analysis of TNFa and IL-1b levels in control
(rs = 0.64, p < 0.01) and asthmatic subjects (rs = 0.49, p < 0.05). (B)
Correlative analysis of IL-6 and TNFa levels in control (rs = 0.46,
p = 0.08) and asthmatic subjects (rs = 0.29, p = 0.24). (C) Correlative
analysis of IL-6 and IL-1b levels in control (rs = 0.38, p = 0.15) and
asthmatic subjects (rs = 0.18, p = 0.48).
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between disease status and lung function is mediated by
IL-6, a decrease in the strength (b-coefficient) of the
relationship between disease status and lung function or
a complete loss of the statistical significance in this rela-
tionship is expected in the multiple regression analysis
[24]. The value of the regression parameter describing
the relationship between FEV1/FVC% predicted and dis-
ease status was decreased in the multiple regression ana-
lysis (b = -11.69) compared with the value in the simple
regression analysis (b = -13.58), but it remained
statistically significant (p = 0.0005) (Table 2). In con-
trast, the statistically significant relationship between
PEFR and disease status in the simple regression analysis
(p = 0.0052) disappeared when IL-6 was included in the
multiple regression model (p = 0.09) (Table 2). These
results suggest that the relationship between disease sta-
tus and lung function could be mediated by IL-6, parti-
cularly when lung function is measured as PEFR.
The dissociation of IL-6 from other proinflammatory
markers (e.g. TNFa and IL-1b) and the well-established
role of IL-6 in the differentiation of CD4
+ T cells, led us
to examine the presence of specific cytokines for defined
effector T cell subsets. Recent studies point to a poten-
tial role of Th17 cells in airway inflammation in asthma.
IL-6 has been shown to promote Th17 cell differentia-
tion in mouse models [12-14], although its contribution
to human Th17 cell development remains controversial
[15-17]. We therefore examined IL-17 (IL-17A) levels in
i n d u c e ds p u t u mf r o mc o n t r o la n dm i l d - m o d e r a t ea s t h -
matic subjects. Although there was no statistically signif-
icant difference in IL-17 levels between the control and
asthmatic groups (Fig. 4A), there seemed to be a subset
of asthmatic patients that had increased IL-17 levels.
Since IL-17 has been associated with neutrophil recruit-
ment we examined the association of this cytokine with
neutrophils in induced sputum. IL-17 levels in the asth-
matic group showed a strong positive correlation with
Figure 3 Relationship of IL-6 with lung function in mild-
moderate asthmatic subjects. (A) Correlative analysis of sputum
IL-6 levels and FEV1/FVC ratio in control (rs = -0.18, p = 0.50) and
asthmatic (rs = -0.23, p = 0.37) subjects. (B) Correlative analysis of
sputum IL-6 levels with PEFR in control (rs = -0.26, p = 0.34) and
asthmatic (rs = -0.37, p = 0.13) subjects. (C) Schematic
representation of the hierarchical regression analysis in the total
cohort. Path X is the correlation between IL-6 levels and disease
status (asthma). Path Y is the correlation between IL-6 levels and
lung function. Path Z is the correlation between disease status and
lung function.
Table 2 Analysis of IL-6 in the relationship between
disease status and lung function
Simple Regression Analyses
Path X
Disease status (asthma) IL-6 (mediator)
10.68
a (2.86)b
p < 0.0007
Path Y
Lung function Parameters
IL-6 (mediator) FEV1/FVC% predicted PEFR
-0.5 (0.16)
p = 0.0025
-0.45 (0.16)
p = 0.0088
Path Z
Lung function Parameters
Disease status (asthma) FEV1/FVC% predicted PEFR
-13.58 (2.51)
p < 0.0001
-9.21 (3.07)
p = 0.0052
Multiple Regression Analyses
Lung function Parameters
FEV1/FVC% predicted PEFR
Disease status (asthma) -11.69 (2.99)
p = 0.0005
-6.34 (3.62)
p = 0.09
IL-6 (mediator) -0.177 (0.15)
p = 0.2594
-0.27 (0.19)
p = 0.1599
a: b-coefficient
b: standard errors
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asthmatic patients did not correlate with the presence of
neutrophils in the airway, further indicating the dissocia-
tion of IL-6 with inflammation (Fig. 4C). Furthermore,
IL-6 levels within the asthmatic population did not cor-
relate with IL-17 levels (Fig. 4D). Thus, in mild-moder-
ate allergic asthma there is no clear association between
IL-6 and the IL-17/neutrophils axis.
IL-6 is also known to promote Th2 polarization while
suppressing Th1 differentiation [10]. We therefore
examined the presence of Th2 (IL-4, IL-5, IL-13) and
Th1 (IFNg) cytokines in induced sputum. IFNg and IL-4
levels were negligible in most of the subjects from both
groups and, therefore, they could not undergo statistical
analysis (data not shown). Low levels of IL-5 could be
detected, but there was no significant difference between
the control and asthmatic groups (Fig 5A). The lack of
increased IL-5 levels in the mild-moderate asthmatic
subjects correlated with the lack of a strong eosinophilic
response in the airway of the asthmatic patients since
the levels of eosinophils in this group were similar
to those in the control subjects (Fig. 5B). In contrast to
IL-5, IL-13 levels were clearly increased in asthmatic
subjects compared with controls (Fig. 5C). Thus, both
IL-6 and IL-13 are selectively elevated in the airway of
mild-moderate asthmatic patients compared with
control subjects. Furthermore, comparative analysis of
these cytokines shows IL-13 levels positively correlate
with elevated IL-6 levels in the asthmatic population
(Fig. 5D). These results further support our recent study
showing IL-6 is required for IL-13 production in an
experimental mouse model of allergic asthma [28].
However, unlike IL-6, analysis of IL-13 in the total
cohort showed no correlation of IL-13 with FEV1/FVC%
predicted (rs = -0.20, p = 0.26) or PEFR (rs = -0.05,
p = 0.76).
Discussion
Over the last decade increasing evidence has shown that
IL-6 can modulate the adaptive immune response dur-
ing early T cell activation. Its ability to influence various
CD4
+ effector T cell subsets suggests that IL-6 may play
a functional role in diseases that are mediated by the
activity of these cells. Despite this body of knowledge,
Figure 4 IL-17 levels in mild-moderate asthmatic subjects and
its relationship to IL-6. (A) IL-17 levels were analyzed in control
and asthmatic subjects. (B) Correlative analysis of IL-17 levels with
percentage of neutrophils in asthmatic subjects (rs = 0.60, p < 0.05).
(C) Correlative analysis of IL-6 levels with percentage of neutrophils
in asthmatic subjects (rs = 0.07, p = 0.83). (D) Correlative analysis of
IL-6 and IL-17 levels in asthmatic subjects (rs = -0.45, p = 0.06).
Figure 5 Selective elevation of IL-13 in mild-moderate
asthmatic subjects compared with healthy control subjects. (A)
IL-5 levels and (B) percentage of eosinophils in induced sputum
were analyzed in the control and asthmatic groups. (C) IL-13 levels
were analyzed in control and asthmatic subjects. (D) Correlative
analysis of IL-6 and IL-13 levels in the asthmatic group (rs = 0.53, p
< 0.05).
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marker with other cytokines such as IL-1b and TNFa in
a variety of immune-mediated diseases. IL-6 is viewed as
a product of an ongoing innate immune response, pri-
marily as a factor derived by activated macrophages
and/or dendritic cells. However, IL-6 can be produced
by cells other than hematopoietic cells, such as epithelial
cells, endothelial cells and fibroblasts, in response to
specific stimuli [9]. Thus, IL-6 could be produced in the
absence of inflammatory cells, and might be a sign of
tissue specific pathology. A good example of this is
Rheumatoid Arthritis where IL-6 has long been used as
a biomarker of disease severity. However, recent clinical
trials with tocilizumab have shown that IL-6 contributes
to both disease severity and progression [29,30]. This
opens up the possibility that in other diseases in which
IL-6 is also elevated, this cytokine may not only be an
indicator of inflammation, but contributes to the initia-
tion and/or progression of disease.
IL-6 has been shown to be increased in chronic
inflammatory diseases of the airway. Increased IL-6
levels in induced sputum have been found in patients
with severe-very severe Chronic Obstructive Pulmonary
Disease (COPD) relative to mild-moderate COPD
patients [31]. In asthma, several reports have also shown
elevated IL-6 levels in BALF and serum as well as
increased IL-6 secretion from lung epithelial cells col-
lected from asthmatics [7,8,32,33]. In this study we
report that IL-6 levels in induced sputum from mild-
moderate allergic asthmatic patients are significantly
increased compared with levels in control subjects and
that neither TNFa,I L - 1 b or MCP-1 was increased in
the asthmatic population. Furthermore, we show that
there is a clear dissociation of IL-6 levels with both IL-
1b and TNFa in the asthmatic group. On the other
hand, IL-1b and TNFa associate with each other. These
results, together with a lack of significant eosinophilia
and neutrophilia in asthmatic subjects, suggest that
there is relatively no inflammation, as classically defined,
within this group of asthmatic patients and that IL-6
detected in the lung microenvironment is not a result of
an inflammatory response. Instead, IL-6 may be indica-
tive of an ongoing process that contributes to the
underlying disease in these patients.
Although no IL-4 could be detected in the induced
sputum of asthmatic patients and IL-5 levels were not
different between the asthmatic and control groups, the
other classical Th2 cytokine IL-13 was selectively
increased in the asthmatic group. We have previously
reported that IL-6 promotes the differentiation of
mouse CD4
+ T cells into Th2 cells that produce IL-4,
but it does not induce IL-5 production [34]. We have
recently shown that a mouse model of allergic airway
inflammation induced by Aspergillus fumigatus extracts
lung exposure induces rapid production of IL-6 in the
airway and that IL-6 is critical for IL-13 production in
the lung microenvironment [28]. The correlation of IL-6
and IL-13 levels in asthmatic patients further support
the interaction between these two cytokines. One of the
major functions of IL-13 is to promote the production
of mucus by airway epithelial cells [35-37]. Mucus
hypersecretion can also contribute to asthma pathology.
Interestingly, minimal mucus production could be
detected in IL-6 deficient mice exposed to A. fumigatus
relative to wild type mice, correlating with their
impaired IL-13 production [28]. Studies in mouse mod-
els have also suggested that IL-13 can modulate airway
hyperresponsiveness by increasing the response of air-
way smooth muscle cells to specific bronchoconstrictors
[36-38]. Thus, the selective elevation of IL-13 relative to
other Th-derived cytokines in this group of asthmatic
patients could contribute to pathological changes in the
airway such as mucus hypersecretion and smooth mus-
cle remodeling that leads to structural changes in the
large conducting airway.
While the role of the Th17 immune response in aller-
gic airway inflammation is still under investigation, early
studies in humans have shown that expression of IL-17
within the airways is associated with increased influx of
neutrophils to the lung and asthma severity [4]. Since
the majority of asthmatic subjects in our study have
relatively mild disease, it was not surprising that IL-17
levels within this group were not statistically different
from the controls. Nevertheless, we show a direct corre-
lation between sputum IL-17 levels and the presence of
neutrophils in the airway was observed in accordance
with previous reports [39]. Although IL-17-producing
mononuclear cells have been found in the lungs of
severe asthmatic patients [4], their identification as bona
fide Th17 CD4
+ T cells has not been fully demonstrated.
While mouse studies have shown IL-6 to be an impor-
tant factor in the differentiation of Th17 cells its role in
the development of the Th17 lineage in humans is less
clear. Some studies have shown that human peripheral
CD4
+ T cells fail to differentiate in the presence of IL-6
and TFGb [15,16] while other reports show that IL-6
augments IL-1b-induced IL-17 production from human
CD4
+ T cells [17]. Our studies suggest that there is not
a clear association of IL-6 with IL-17 in the airway of
mild-moderate allergic asthmatics.
The selective presence of IL-6 in the sputum of asth-
matic patients without active inflammation suggests a
potential role of this cytokine in the maintenance of
the disease instead of merely being a non-specific mar-
ker of inflammation. In support of this concept, recent
studies have shown that sputum IL-6 levels inversely
correlates with lung function as determined by FEV1%
predicted and FEV1/FVC in patients with COPD [40].
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substantial number of subjects with severe asthma
h a v es h o w na ni n v e r s ec o r r e l a t i o no fI L - 6i ni n d u c e d
sputum with FEV1% predicted in a cohort of asth-
matics [23,41]. In the current study, we show that IL-6
does not correlate with FEV1/FVC% predicted, but
there is a trend towards an inverse correlation with
PEFR in the asthmatic group. Furthermore, the hier-
archical regression analysis in the total cohort shows
that the relationship between disease status and lung
function (as determined preferentially by PEFR) is
mediated by IL-6. Thus, IL-6 can contribute to
increase airway obstruction in asthma. This type of
statistical analysis requires a significant relationship
between the mediator (cytokines) and disease status,
and between the mediator and lung function. Because
the other examined cytokines were not statistically sig-
nificantly related to disease status (e.g. IL-1b,T N F a,
MCP-1, IL-5, and IL-17) and/or lung function (e.g. IL-
13) in the total study cohort, the final step in the ana-
lysis exploring a mediator function (i.e. the multiple
regression analysis) was not performed.
In addition to modulating the type of CD4
+ T cell
response, the current data suggest that IL-6 could also
influence lung physiology by promoting an increase in
airway wall thickness, subepithelial fibrosis, and
smooth muscle hypertrophy and proliferation, as sup-
ported by animal and human studies [42-45]. Accumu-
lation of IL-6 within the mild-moderate asthmatic
group may reflect cellular processes that are occurring
within the larger airways since previous studies have
shown that induced sputum collection occurs within
the central rather than peripheral airways [46]. The
inverse association that IL-6 has with measures of cen-
tral airway function such as PEFR and, to a lesser
extent with FEV1/FVC, in the total study cohort sug-
gests central airway remodeling is mediated by IL-6.
Undoubtedly, the significance of elevated sputum IL-6
in allergic asthma remains unclear. Future studies on
the role of IL-6 in the pathophysiology of asthma are
warranted and depending on the results from these
studies, IL-6 could be a potential therapeutic target in
this disease.
Conclusions
In summary, this study has shown that IL-6, rather than
TNFa or IL-1b, is elevated in induced sputum from
mild-moderate allergic asthmatic subjects, and that IL-6
positively correlates with increased IL-13 levels within
this patient population. Furthermore, our data also sug-
gests that IL-6 contributes to impaired lung function in
allergic asthma. IL-6 is therefore more than a proinflam-
matory marker in the lung and may play a role in the
pathophysiology of asthma.
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